(Q21129272)

English

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

scientific article

In more languages

Statements

scholarly article

0 references

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (English)

0 references

18

object named as

Ulrich Schwabe

author given names

Ulrich

author last names

Schwabe

1 reference

PubMed publication ID

15 August 2022

object named as

Brian Godman

1

author given names

Brian

author last names

Godman

1 reference

PubMed publication ID

15 August 2022

Lars L. Gustafsson

object named as

Lars L Gustafsson

24

author given names

Lars L

author last names

Gustafsson

1 reference

PubMed publication ID

15 August 2022

Björn Wettermark

2

object named as

Bjorn Wettermark

author given names

Bjorn

author last names

Wettermark

1 reference

PubMed publication ID

15 August 2022

Kristina Garuoliene

12

author given names

Kristina

author last names

Garuoliene

object named as

Kristina Garuoliene

1 reference

PubMed publication ID

15 August 2022

15

author given names

Ott

author last names

Laius

object named as

Ott Laius

1 reference

PubMed publication ID

15 August 2022

Catherine Sermet

17

author given names

Catherine

author last names

Sermet

object named as

Catherine Sermet

1 reference

PubMed publication ID

15 August 2022

23

author given names

Corinne

author last names

Zara

object named as

Corinne Zara

1 reference

PubMed publication ID

15 August 2022

Alexander E Finlayson

10

author given names

Alexander E

author last names

Finlayson

object named as

Alexander E Finlayson

1 reference

PubMed publication ID

15 August 2022

Menno van Woerkom

3

author given names

Menno

author last names

van Woerkom

object named as

Menno van Woerkom

1 reference

PubMed publication ID

15 August 2022

11

author given names

Jurij

author last names

Fürst

object named as

Jurij Fürst

1 reference

PubMed publication ID

15 August 2022

13

author given names

Harald

author last names

Herholz

object named as

Harald Herholz

1 reference

PubMed publication ID

15 August 2022

14

author given names

Marija

author last names

Kalaba

object named as

Marija Kalaba

1 reference

PubMed publication ID

15 August 2022

author name string

Jessica Fraeyman

4

author given names

Jessica

author last names

Fraeyman

1 reference

PubMed publication ID

15 August 2022

Samantha Alvarez-Madrazo

5

author given names

Samantha

author last names

Alvarez-Madrazo

1 reference

PubMed publication ID

15 August 2022

Christian Berg

6

author given names

Christian

author last names

Berg

1 reference

PubMed publication ID

15 August 2022

Iain Bishop

7

author given names

Iain

author last names

Bishop

1 reference

PubMed publication ID

15 August 2022

Anna Bucsics

8

author given names

Anna

author last names

Bucsics

1 reference

PubMed publication ID

15 August 2022

Stephen Campbell

9

author given names

Stephen

author last names

Campbell

1 reference

PubMed publication ID

15 August 2022

Jutta Piessnegger

16

author given names

Jutta

author last names

Piessnegger

1 reference

PubMed publication ID

15 August 2022

Vera V Vlahović-Palčevski

19

author given names

Vera V

author last names

Vlahović-Palčevski

1 reference

PubMed publication ID

15 August 2022

Vanda Markovic-Pekovic

20

author given names

Vanda

author last names

Markovic-Pekovic

1 reference

PubMed publication ID

15 August 2022

Luka Vončina

21

author given names

Luka

author last names

Vončina

1 reference

PubMed publication ID

15 August 2022

Kamila Malinowska

22

author given names

Kamila

author last names

Malinowska

1 reference

PubMed publication ID

15 August 2022

language of work or name

0 references

publication date

2014

0 references

Frontiers in Pharmacology

0 references

5

0 references

106

0 references

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Generic medicines: solutions for a sustainable drug market?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Pharmacist-patient communication in Swedish community pharmacies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Policies to enhance prescribing efficiency in europe: findings and future implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

What principles should govern the use of managed entry agreements?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Getting better value from the NHS drug budget

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

A systematic review and meta-analysis on the therapeutic equivalence of statins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

12 September 2017

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

27 September 2017

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

27 September 2017

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

27 September 2017

Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

30 May 2018

Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Generic atypical antipsychotic drugs in Belgium: their influence and implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Potential savings without compromising the quality of care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Enhancing the rational use of new medicines across European health care systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4060455

29 November 2018

Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24987370

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

1 reference

https://pubmed.ncbi.nlm.nih.gov/24987370

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24987370

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What lessons can be learned from the launch of generic clopidogrel?

1 reference

https://api.crossref.org/works/10.3389%2FFPHAR.2014.00106

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.3389/FPHAR.2014.00106

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_wnfa7genb5ey3bxrzephlrfrpa

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21129272&oldid=2043567620"